Human PCSK9 ELISA Kit
产品概述（Product Details）
Human PCSK9 ELISA Kit is a ready-to-use immunoassay kit, specifically designed to quantitate natural and recombinant human PCSK9 that is present in biological samples, such as human serum, plasma, and cell culture supernatants. Our ELISA Kit provides several benefits:
Standards to calibrate with NIBSC/WHO standards for comparable results.
Fully validation in biologic samples for detection range, sensitivity, inter- and intra-plate CV, recovery, dilution linearity, specificity, and matrix effects to ensure reliable results according to ICH M10 guideline.
High-quality antibody pairs and protein standards, along with rigorous quality control, to guarantee consistent results across different batches.
Simplified and straightforward protocols and ready-to-use reagents to save assay time.
应用说明（Application）
The kit is developed for quantitative detection of natural and recombinant human PCSK9 in serum, plasma and cell culture supernatants.
It is for research use only.
流程图（Workflow）
关键信息（Key Features）
Elevate your research experience with our Cytokine/Biomarker Detection Kits, where accuracy, reliability, and ease of use are converging to deliver exceptional results.
存储（Storage）
Keep the unopened kit stored at 2-8 °C. Avoid using the kit beyond its expiration date. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
关键字： PCSK9;PCSK9试剂盒;PCSK9 ELISA试剂盒;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。